Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Technoderma Starts US Trial of JAK1/Tyk2  Inhibitor for Atopic Dermatitis

publication date: Feb 9, 2023

Jiaxing Technoderma Medicines has begun a US Phase I trial of a clinical stage topical ointment that is intended to treat Atopic Dermatitis. TDM–180935 is a small molecule JAK1/Tyk2 small molecule inhibitor that suppresses both keratinocyte- and T cell-derived pathogenic pathways, an important channel for Atopic Dermatitis. Technoderma believes the candidate may offer better efficacy and safety than existing topical treatments. The trial enrolled healthy male volunteers who will be administered ascending single and multiple doses of TDM-180935.  Technoderma develops treatments for dermatological conditions. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital